Hematogenix MRD Assay Used in FDA Approval of ZENBEXUS for Myeloma

Hematogenix's next generation flow cytometry assay was the analytical method supporting the FDA accelerated approval of Bristol Myers Squibb's ZENBEXUS for multiple myeloma, marking the first approval of a CELMoD therapy. The assay measured MRD-negative complete response, a primary efficacy endpoint, validating its role in regulatory approval pathways for cancer therapies.

This Wire brief sits within Fusion42's coverage of Biotech.